https://doi.org/10.31288/oftalmolzh201712528

Comparison of expression of molecular markers of peripheral blood lymphocyte activation in patients with small uveal melanoma and healthy controls
S.I. Poliakova, Dr Sc (Med)
L.N. Velichko, Cand Sc (Med)
A.V. Bogdanova, Cand Sc (Biol)
I.V. Tsukanova, Junior Researcher
Filatov Institute of Eye Disease and Tissue Therapy
Odessa, Ukraine
E-mail: inna.sister@mail.ru
Background: Organ-saving treatment is indicated for patients with small (i.e., ? 3 mm in prominence) uveal melanomas (UM), that being the initial stage of the disease. Association between the level of activation of the immune system and the progress of UM has been demonstrated in recent decades. Investigation of the expression of molecular markers of lymphocyte activation is important and required for predicting tumor responses to various treatments and choosing the most effective treatment for the disease.
Purpose: To investigate the expression of molecular markers of peripheral blood lymphocyte activation in patients with small uveal melanomas prior to treatment.
Methods: We compared the expression of molecular markers of peripheral blood lymphocyte activation in 16 patients with small uveal melanoma (prior to treatment) and 44 healthy controls (donors).
Results: Prior to treatment, patients with small uveal melanoma were found to have elevated expression of molecular markers of peripheral blood lymphocyte activation compared to healthy controls (р < 0.0002).
Conclusion: In uveal melanoma patients at the initial stage of the disease (i.e., with tumors ? 3 mm in prominence), the functional activity of immune competent cells of the body in response to tumor development was found to involve the following: (a) activation of lymphocyte IL-2 receptors (CD25+), (b) increased indices of lymphocyte activation and proliferation (CD38+, CD45+, CD150+),  immunoglobulin production (CD150+), and intercellular adhesion (CD54+) and apoptosis (CD 95+), and (c) induction of cytokine secretion (CD7+).
Key words: small uveal melanoma, molecular markers of peripheral blood lymphocyte activation.   
References
1.    Terent’ieva LS, Kotova VA, Shambra VV. [Variation of radiation sensitivity of melanoma as a function of tumor size and irradiation conditions]. Oftalmol Zh. 1993;1:5-7 Russian
2.    Blom DJ, Luyten GP, Mooy C. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997 Aug;38(9):1865-72.
3.    Vetter CS, Lieb W, Br?cker EB, Becker JC. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer. 2004 Oct 18;91(8):1495-9.
       Crossref   Pubmed
4.    Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr;6(4):345-52.
       Crossref   Pubmed
5.    M?kitie T, Summanen P, Tarkkanen A, Kivel? T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1414-21.
6.    Velichko LN. [Expression of molecular markers of peripheral blood lymphocyte activation in uveal melanoma patients with various efficacy of organ-saving treatment]. Oftalmol Zh. 2013;5:9-13 Russian
       Crossref
7.    Gluzman DF, Sklyarenko LM, Nadgornaya VA, Kryachok IA. [Diagnostic immunocytochemistry of tumors]. Kiev: Morion; 2003. 156 p.  Russian
8.    Berezhnaia NM, Chekhun VF. [Immunology of malignant growth]. Kyiv: Naukova Dumka; 2005. 790 p. Russian